Trial Profile
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Capecitabine
- Indications Breast cancer; Gastrointestinal cancer
- Focus Adverse reactions
- 06 Sep 2016 Status changed from active, no longer recruiting to completed.
- 23 Jul 2012 New trial record